Trial Profile

A Single-arm, Forward-looking, Exploratory Clinical Study of Telitacicept in Patients With Refractory IgA Nephropathy

Status: Not yet recruiting

Phase of Trial: Phase II/III

Latest Information Update: 27 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telitacicept (Primary)
Indications IgA nephropathy
Focus Therapeutic Use

Most Recent Events

22 Feb 2023 Protocol amended due to changes in Study phase design and planned patient number.
22 Feb 2023 Planned number of patients changed from 182 to 40.
22 Feb 2023 Planned initiation date changed from 1 Jan 2023 to 1 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com